{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:02:18Z","timestamp":1776812538805,"version":"3.51.2"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["EMA\/2017\/09\/PE"],"award-info":[{"award-number":["EMA\/2017\/09\/PE"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Digital Health"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.landig.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:24:04Z","timestamp":1744165444000},"page":"100861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study"],"prefix":"10.1016","volume":"7","author":[{"given":"Hector","family":"Gonzalez Dorta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Verbeeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Crevecoeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neilshan","family":"Loedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cohet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lander","family":"Willem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Molenberghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niel","family":"Hens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Quinten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.landig.2025.02.001_bib3","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.47.2101001","article-title":"Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January\u2013September 2021","volume":"26","author":"Sacco","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.landig.2025.02.001_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cpt.2828","article-title":"Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency","volume":"113","author":"Durand","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.landig.2025.02.001_bib11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID's role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.landig.2025.02.001_bib14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.landig.2025.02.001_bib15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.landig.2025.02.001_bib16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.landig.2025.02.001_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.3918","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.landig.2025.02.001_bib19","author":"Molenberghs"},{"key":"10.1016\/j.landig.2025.02.001_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/2168479017696260","article-title":"The benefit-risk assessment of medicines: experience of a consortium of medium-sized regulatory authorities","volume":"51","author":"McAuslane","year":"2017","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.landig.2025.02.001_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2010.00725.x","article-title":"A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group","volume":"13","author":"Guo","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.landig.2025.02.001_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40264-020-00982-9","article-title":"Benefit-risk assessment of vaccines. Part II: proposal towards consolidated standards of reporting quantitative benefit-risk models applied to vaccines (BRIVAC)","volume":"43","author":"Arlegui","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.landig.2025.02.001_bib25","author":"Bollaerts"},{"key":"10.1016\/j.landig.2025.02.001_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40264-018-0658-y","article-title":"Benefit-risk monitoring of vaccines using an interactive dashboard: a methodological proposal from the ADVANCE project","volume":"41","author":"Bollaerts","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.landig.2025.02.001_bib27","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.vaccine.2022.04.004","article-title":"Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine","volume":"40","author":"Mayfield","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.landig.2025.02.001_bib28","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1016\/j.vaccine.2023.07.037","article-title":"A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States","volume":"41","author":"Wallace","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.landig.2025.02.001_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/wics.1539","article-title":"Modern Monte Carlo methods for efficient uncertainty quantification and propagation: a survey","volume":"13","author":"Zhang","year":"2021","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"key":"10.1016\/j.landig.2025.02.001_bib30","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/pds.5631","article-title":"Assessing heterogeneity of electronic health-care databases: a case study of background incidence rates of venous thromboembolism","volume":"32","author":"Russek","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.landig.2025.02.001_bib31","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202871119","article-title":"Pandemic origins and a One Health approach to preparedness and prevention: solutions based on SARS-CoV-2 and other RNA viruses","volume":"119","author":"Keusch","year":"2022","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Lancet Digital Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589750025000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589750025000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:34:18Z","timestamp":1748558058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589750025000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2589750025000251"],"URL":"https:\/\/doi.org\/10.1016\/j.landig.2025.02.001","relation":{},"ISSN":["2589-7500"],"issn-type":[{"value":"2589-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Digital Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.landig.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100861"}}